Crescent Biopharma's total assets for Q4 2025 were $240.29M, an increase of 73.79% from the previous quarter. CBIO total liabilities were $37.28M for the fiscal quarter, a 72.37% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.